Mississauga, Ontario, Canada (May 23, 2012) Therapure Biopharma Inc. is pleased to announce today that it has been awarded the Gold Leaf Award for Emerging Company of the Year by BIOTECanada in the Health Biotech Category for 2012. Therapure has been recognized as an outstanding emerging health company for the potential of its unique biomanufacturing capabilities as well as its highly innovative drug discovery pipeline.
“Therapure has distinguished themselves among their peers with incredible technology innovation,” commented Brad Thompson, Chair BIOTECanada. “Their scientific dedication is one we can all be proud. Therapure is providing paramount service to partners across Canada and internationally.”
“Therapure is privileged to receive this award and honoured to be recognized by our industry peers. Our growth is based on a strong foundation of protein manufacturing expertise as well as a rich pipeline of drug development candidates. We look forward to continued growth and expansion opportunities”, said Nick Green, President and CEO of Therapure.
Since its launch into the Contract Development and Manufacturing Organization (CDMO) space in 2008, Therapure has achieved impressive growth including the execution of more than 30 service contracts with a broad spectrum of Canadian and international customers.
In addition to its CDMO services, Therapure also has a portfolio of internal drug development programs focused on liver cancer, hepatitis C and chemotherapy-induced anemia. Therapure’s drug discovery pipeline is built on a deep knowledge and understanding of hematology.
“2011 was a year of significant achievement for Therapure,” said Mr. Green. “Amongst many achievements, the following are just some of the highlights:
· Expansion of Therapure’s CDMO service offering through the acquisition of mammalian cell culture bioreactor’s increasing our capacity to 2,500L.
· Completion of a major facility retrofit in support of our long term supply agreement for the purification and fill/finishing of plasma protein therapeutics.
· Expansion of Therapure’s cGMP clean room space by 2,153 sq. ft. in support of our growing customer base.
· Significant progress on our liver cancer and chemotherapy induced anemia programs which are now targeted to enter Phase I clinical trials late 2012/early 2013.”
Join us as we celebrate our achievement during the BIO International Convention (BIO) at the Boston Convention & Exhibition Center. Therapure will be presented its Gold Leaf Award at BIO on June 19, 2012 at 4pm at the Canada Café (booth number 735). As well, please visit the Therapure team at Booth #2651 to discuss your manufacturing needs and how Therapure may be of assistance.
ABOUT THERAPURE BIOPHARMA
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins and biosimilars. As a contract development and manufacturing organization (CDMO), Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada-licensed 130,000 sq. ft. facility includes manufacturing, research and quality-control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMA, MHRA and Health Canada standards.
For more information, please visit: www.therapurebio.com
Director, Marketing and Special Projects